GlassScriptPhysician profile
Brandon M Stone
NPI 1376855981
$3,205.91
in general payments reported to CMS, 2019-2025
40 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $37.87 · 2022: $798 · 2023: $646 · 2024: $660 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $615.63 | 2019-2025 | |
| Janssen Biotech, INC. | $447.65 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Janssen Scientific Affairs, LLC | $266.44 | 2022-2023 | |
| Astellas Pharma US INC | $212.23 | 2019-2024 | Xtandi, Xospata |
| Eagle Pharmaceuticals, INC. | $168.08 | 2022-2024 | |
| Octapharma USA, INC. | $151.97 | 2022 | |
| Abbvie INC. | $114.75 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $99.36 | 2019-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $98.13 | 2019-2025 | Lynparza |
| Daiichi Sankyo INC. | $97.89 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $78.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.11 | 2019 | |
| Incyte Corporation | $70.22 | 2019-2024 | Monjuvi, Pemazyre |
| Amgen INC. | $68.16 | 2019 | |
| Emd Serono, INC. | $54.77 | 2023-2025 | Bavencio |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.